🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Looking forward to #ASCO2023! Visit us at booth #23091 to see how we're closing the #healthequity gap in cancer. 🗓️ Schedule a meeting: ow.ly/7YBP50OuyAi

The countdown to #ASCO2023 is on! Meet our team at booth 23091 and see how we deliver cost-effective #cancertesting to patients no matter where they seek treatment. 🗓️ ow.ly/OEeh50OyYpN

#UterineCancer is the most common #gynecologic cancer among women in high-income countries, with incidence and death rates rising yearly. This June, we're joining IGCS and International Gyn Cancer Advocacy Network to raise awareness and give it the attention it needs to reverse this trend!

A great weekend at #ASCO2023! Come see us at booth 23091.

Cancer affects everyone– globally, 1 in 5 people develop one. Advances in #research make survivorship more common, so on this National #CancerSurvivors Day, we’re taking a moment to celebrate life while also shining a light on the challenges that come with it. #NCSD2023

Closing off #ASCO2023 with that energy! 🙌 Stop by booth 23091 to see how we’re closing the #healthequity gap in cancer.

Another great week at #ASCO2023 with the team! A special thank you to those who stopped by our booth. Any questions we’ve missed? Write to us at [email protected]

Tumor grade & estrogen receptor status enable stratification of clinical outcomes in #endometrialcancer. Read on to see how this revolutionizes classification and its clinical significance for patients 👉 bit.ly/3oQgf8n IGCS Vancouver Coastal Health #uterinecancer

Bonjour #Paris ! Notre responsable de la recherche clinique, Pierre Couture, participera au congrès IFODS. Pour prendre rendez-vous, écrivez-nous à [email protected] ifods.com

Looking forward to #AMPEurope2023 in Milan! To schedule a meeting with our Lead for Clinical Outreach, contact [email protected]. amp-europe-congress.com

Dr. Huntsman's desire to increase the clinical impact of his research continues to drive us- developing cost-effective cancer testing for patients no matter where they live. Congrats to our co-founder on the honorary degree! Memorial University SaltWire ow.ly/AU7J50ON9ok

We're committed to providing cost-effective solutions for patients seeking treatment. Our collaboration with Dr. McAlpine's lab showcases this mission in action for #endometrialcancer. Learn more on our latest #blog: bit.ly/3oQgf8n

Join us at the Colorectal Cancer Resource & Action Network #Biomarker conference as we address barriers and unequal access to timely #moleculartesting results in #cancer care. Our CSO, Vincent Funari, is a panelist discussing the readiness for ctDNA testing in Canada. Register here: ow.ly/QoVl50ORQUw

Our Vancouver office participated in the Father’s Day Run/Walk this Sunday. Special shoutout to Kevin Tam, a long-time @ProstateCancrBC volunteer who got the group together for a great cause!

This past week, our Lead for Clinical Outreach, Pierre Couture, connected with the EU #oncology community at Congrès IFODS and #AMPEurope. Thank you for the engaging discussions! #OnTheRoad

Wishing our Canadian colleagues and collaborators a bright and happy #CanadaDay weekend!

Project ACTT was an initiative to speed up testing for #cancerpatients during the pandemic through a simple blood draw leveraging #liquidbiopsy technology. This partnership with DynaLIFE now extends its success for #lungcancer patients in #Alberta. ow.ly/GOIK50P8TQN

Our collaborative study with Dr. Natasha Leighl of University Health Network shows pilot data on using #liquidbiopsy testing earlier in a #lungcancer patient’s journey, which shortened the time from referral to treatment by 50%. 👉 Full paper: ow.ly/T8em50Pelkt

Looking forward to #GCGAnnual2023! To see how we’re leveraging AI expertise with advanced #molecularbiopsy solutions to close the #healthequity gap in cancer, schedule a meeting with us! 🗓️ ow.ly/oIkR50Pemhw

Our latest study delves into the potential of non-invasive #biomarkers for predicting immune checkpoint inhibitor response in #NSCLC. Discover how we designed generalizable multimodal #AImodels that demonstrate a path to clinical utility. ow.ly/GILw50PjNWG